CGEM · Cullinan Therapeutics, Inc.
AI read · Good for CGEM
The AI's read
The findings give Cullinan early evidence that CLN-049 can produce responses in people with hard-to-treat blood cancers. The two-step schedule also had fewer and milder cytokine reactions. This is still an early study. Severe fever with low blood cell counts, liver enzyme rises, and pneumonia occurred. The response and dosing results favor the drug program, but Phase 2 testing is still ongoing.